Bladder cancer development leader who helped drive recent FDA product approval in NMIBC joins to lead research and development strategy Appointment strengthens enGene’s clinical development and regulatory capabilities ahead of planned 2H 2026 BLA submission for detalimogene BOSTON & MONTREAL — enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicine […]